Israel prepares for possible U.S. green light to strike Iran ballistic missile sites
Israel is preparing for the possibility of receiving a green light from the United States to launch strikes against Iran’s ballistic missile system,...
Beijing, February 24, 2025 – A newly identified bat coronavirus, designated HKU5-CoV-2, has been found to enter human cells using the same cell-surface protein as SARS-CoV-2, the virus responsible for COVID-19, according to a study published in the journal Cell.
While the virus possesses key features such as a furin cleavage site that facilitates entry via the ACE2 receptor, researchers noted that it does not infect human cells as efficiently as SARS-CoV-2.
In laboratory experiments, HKU5-CoV-2 successfully infected human cells with high ACE2 levels in both test tube assays and in models simulating human intestinal and airway tissues. The study further identified several monoclonal antibodies and antiviral drugs capable of targeting the bat virus, offering potential avenues for preemptive therapeutic strategies.
The research has attracted significant market attention; Bloomberg reported that news of the study influenced a modest rise in shares of several COVID vaccine manufacturers, including Pfizer, Moderna, and Novavax. However, infectious disease expert Dr. Michael Osterholm from the University of Minnesota cautioned that the reaction might be “overblown.” He pointed to the extensive preexisting immunity in the global population against similar SARS viruses and the markedly lower binding affinity of HKU5-CoV-2 to human ACE2 compared with SARS-CoV-2, factors that could mitigate the pandemic risk.
While the discovery highlights a potential pathway for zoonotic spillover, the authors of the study stressed that several suboptimal factors for human adaptation suggest that the risk of this bat virus emerging as a human pathogen should not be exaggerated. The findings add to the growing body of research on coronaviruses and underscore the importance of continued surveillance of wildlife pathogens.
Ruben Vardanyan has been sentenced to 20 years in prison by the Baku Military Court after being found guilty of a series of offences including war crimes, terrorism and crimes against humanity.
The drumbeats have finally faded at the Marquês de Sapucaí, bringing the competitive phase of the Rio Carnival 2026 to a dazzling close. Over two marathon nights of spectacle, the twelve elite schools of the "Special Group" transformed the Sambadrome into a riot of colour.
President Donald Trump said he will be involved “indirectly” in nuclear negotiations between the United States and Iran in Geneva, as both sides resume diplomacy against a backdrop of military pressure and deep mistrust.
Peru’s Congress has voted to censure and remove José Enrique Jeri Ore from his posts as President of Congress and acting President of the Republic, just four months into his tenure, citing undisclosed meetings with Chinese businessmen and alleged hiring irregularities.
Start your day informed with AnewZ Morning Brief: here are the top news stories for the 17th of February, covering the latest developments you need to know.
U.S. President Donald Trump on Wednesday sought to highlight his outreach to Black Americans during a White House reception marking Black History Month, held months before November’s midterm elections.
Hungary and Slovakia announced a suspension of diesel exports to Ukraine on Wednesday.
A platoon of Swedish Air Force Rangers is training in Greenland as part of the ongoing “Arctic Endurance” exercise, according to Sweden’s military.
U.S.-mediated talks between Russia and Ukraine in Geneva ended after two days of negotiations that Ukrainian President Volodymyr Zelenskyy described as difficult, while signalling progress on the military track.
Millions of Muslims around the world have begun observing Ramadan, the ninth month of the Islamic lunar calendar and the most sacred period in Islam.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment